For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...

Get rid of smoking reminders - wash the jacket you wear to take smoke breaks, clean your car, get rid of matches, ashtrays ...

Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...

Implemented in 2023, ResMed’s 2030 Operating Model reorganized the company to ensure it remains product-led, customer-centric, and brand-enhanced. The 2030 Operating Model further accelerates ResMed’s ...

Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...

The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...

The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...

In adults with undiagnosed respiratory symptoms, dyspnea impact was worse in those with PRISm vs undiagnosed asthma or COPD.

The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

The second annual World Oxygen Day, led by the COPD Foundation and supported by Nonin, will be held Oct. 2. The day brings together more than a dozen global patient advocacy organizations and ...

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...